Have you seen the ad where Kevin Nealon says he prefers Xarelto (rivaroxaban) over warfarin because it allows him to eat a healthy salad if he wants to? His statement makes it sound like Xarelto is a healthier choice, but the reason why you can eat leafy greens while taking Xarelto is the very thing that makes it such a dangerous medication. … [Read more...]
FDA Confirms Serious Risks of Invokana and Other SGLT2 Inhibitors
In May, 2015, the U.S. Food and Drug Administration (FDA) announced that it would conduct a safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as Invokana, used to treat type 2 diabetes. The Agency announced the results of the review on December 4. SGLT2 inhibitors will now carry new warnings about the risks of ketoacidosis … [Read more...]
Defective Device Used in Xarelto Trial
The European Medicines Agency (EMA) is questioning the results of a clinical trial called ROCKET AF, that compared Xarelto (rivaroxaban) with warfarin for preventing stroke in patients with nonvalvular atrial fibrillation (AFib). A defective device was used in the trial, and regulators are worried that the defect may have resulted in inaccurate … [Read more...]
Xarelto Injury Lawsuits
More than 1,900 Xarelto (rivaroxaban) lawsuits have been filed against Bayer and Johnson & Johnson (J&J), and the number is expected to pass 2,000 soon. A recently published study, funded by Bayer, concluded that Xarelto is safe. Several other studies, not funded by the drug maker, came to far less favorable conclusions. Xarelto can cause … [Read more...]
Zofran Birth Defect Lawsuits
There are over 60 lawsuits pending against GlaxoSmithKline (GSK), maker of Zofran (ondansetron), by the parents of babies who suffered birth defects after their mothers took the drug to relieve morning sickness during pregnancy. On October 13, 2015, the U.S. Judicial Panel on Multidistrict Litigation issued a transfer order consolidating all … [Read more...]
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 45
- Next Page »
Recent Comments